Cue Biopharma. Every tracked FinTwit mention of $CUE, newest first. 4 mentions since the first on May 19, 2026. See the price chart.
May 2026 · 4 mentions
May 19
InvestmentGuru — $CUE
Wrapping up the day still thinking about $CUE — at ~$110M market cap you’re getting a validated immunology platform, a Boehringer Ingelheim partnership worth up to $345M in m…↗
May 19
InvestmentGuru — $CUE
The part that doesn’t get enough attention:
Boehringer Ingelheim didn’t just partner with them. They keep paying milestones.
That’s big pharma saying the platform still w…↗
May 19
InvestmentGuru — $CUE — micro-cap biotech turnaround worth watching.
→ Market cap ~$110M
→ Collaboration revenue: $0.4M → $5.7M YoY
→ Net loss cut from $12.3M to $5.2M
→ $30M financing + Boehringe…↗
May 19
InvestmentGuru — $CUE
One Small-Cap Immunology Name.
Cue Biopharma is building a precision immunology platform designed to selectively activate only disease-relevant T cells — potentially avoid…↗